Fusion Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Fusion Pharmaceuticals hat ein Gesamteigenkapital von $241.8M und eine Gesamtverschuldung von $49.7M, was einen Verschuldungsgrad von 20.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $323.8M bzw. $82.0M.

Wichtige Informationen

20.5%

Verhältnis von Schulden zu Eigenkapital

US$49.69m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$210.53m
Eigenkapital	US$241.83m
Gesamtverbindlichkeiten	US$81.98m
Gesamtvermögen	US$323.81m

Jüngste Berichte zur Finanzlage

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05

Recent updates

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Mar 03

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Jan 30

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Sep 16

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Aug 29

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Aug 10

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Aug 09

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Jun 23

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Jan 16

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Aug 28

Fusion Pharma trades higher on early-stage data for cancer therapy

Jun 14

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Apr 05

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Mar 01

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

Jan 25

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

Dec 21

Fusion Pharmaceuticals EPS misses by $0.04

Nov 10

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer

Nov 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: FUSNDie kurzfristigen Aktiva des Unternehmens ($220.9M) übersteigen seine kurzfristigen Passiva ($20.8M).

Langfristige Verbindlichkeiten: FUSNDie kurzfristigen Vermögenswerte des Unternehmens ($220.9M) übersteigen seine langfristigen Verbindlichkeiten ($61.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: FUSN über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: FUSNDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 3.8% auf 20.5% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: FUSN auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: FUSN verfügt über eine ausreichende Liquiditätsreserve für 2.2 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 31.4% pro Jahr abnimmt.

Fusion Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Fusion Pharmaceuticals Files Form 15

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

Recent updates

Fusion Pharmaceuticals Files Form 15

Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.45 loss in 1Q 2023)

Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.55 loss in 3Q 2022)

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

Consensus EPS estimates fall by 11%

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca AB entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.8 billion.

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Price target increased by 34% to US$18.80

AstraZeneca PLC (LSE:AZN) entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (NasdaqGS:FUSN) for $1.5 billion.

Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook

Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?

Price target increased by 7.5% to US$14.27

Consensus revenue estimates increase by 266%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fusion Pharmaceuticals Inc. Announces Board Changes

Fusion Pharmaceuticals Inc. Announces Presentation of Preclinical Data Supporting FPI-2068, A Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers

Consensus revenue estimates increase by 160%

New minor risk - Share price stability

Consensus revenue estimates increase by 304%

Consensus revenue estimates fall by 91%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Fusion Pharmaceuticals Inc. to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

Consensus revenue estimates increase by 289%

New major risk - Shareholder dilution

Fusion Pharmaceuticals Inc. announced that it expects to receive $20 million in funding from Federated Hermes, Inc.

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T

Fusion Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2023

Price target decreased to US$13.95

Fusion Pharmaceuticals Appoints Dmitri Bobilev as Chief Medical Officer

Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors

Fusion Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 in Patients with Advanced Solid Tumors Expressing FGFR3

Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment

Independent Director recently bought US$90k worth of stock

Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?

Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M

Price target decreased to US$16.14

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiopharmaceutical Targeting Solid Tumors Expressing NTSR1

Fusion Pharma wins FDA nod to start trials for solid tumor candidate

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

Fusion Pharmaceuticals Inc. Provides Updates on FPI-1434 and FPI-1966 Clinical Programs

Consensus revenue estimates fall by 84%

Fusion Pharmaceuticals Inc. Announces Executive Changes

Price target decreased to US$18.20

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development

Price target decreased to US$19.00

We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate

Price target decreased to US$21.33

Consensus revenue estimates fall to US$173.7k

Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434

Fusion Pharma trades higher on early-stage data for cancer therapy

Consensus forecasts updated

We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely

New 90-day low: US$11.25

How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?

Fusion Pharmaceuticals Appoints Philina Lee to Its Board of Directors

New 90-day low: US$11.26

Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?

New 90-day low: US$11.56

Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation

TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, A Cancer-Fighting Medical Isotope

Fusion Pharmaceuticals Inc. Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors

Fusion Pharmaceuticals EPS misses by $0.04

New 90-day high: US$13.73

Fusion Pharmaceuticals Inc. Appoints Barbara Duncan as Chairperson of the Board of Directors

Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer